Dasatinib and Quercetin Reach the Brain in Early Alzheimer's Patients
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Summary
Researchers at UT Health San Antonio ran a proof-of-concept pilot trial to find out whether dasatinib and quercetin — two drugs known to clear senescent cells — can actually reach the brain in people with early Alzheimer's disease. The team measured drug levels in cerebrospinal fluid, which directly bathes the brain, to confirm penetration. This matters because senolytics have already shown promise in animal models of Alzheimer's, clearing harmful senescent cells that accumulate in aging brain tissue. Before testing whether the drugs reduce symptoms, scientists first needed to confirm the drugs get where they need to go. This completed Phase 1/2 study represents an early but critical step toward a potential new class of Alzheimer's treatments targeting cellular aging rather than amyloid alone.
Detailed Summary
Alzheimer's disease remains one of the most urgent unsolved challenges in medicine, with existing treatments offering only modest symptomatic relief. A growing body of research implicates senescent cells — aged, dysfunctional cells that resist normal death — as contributors to neuroinflammation and neurodegeneration. Senolytics, drugs that selectively eliminate these cells, have emerged as a promising therapeutic strategy.
This completed Phase 1/2 pilot trial, conducted at the University of Texas Health Science Center at San Antonio, asked a fundamental pharmacokinetic question: do dasatinib (a cancer drug) and quercetin (a plant-derived flavonoid), when taken together, actually penetrate the blood-brain barrier and reach the central nervous system in older adults with early Alzheimer's disease? The team measured drug concentrations in cerebrospinal fluid (CSF) collected from participants — the most direct method to confirm brain exposure.
The study was explicitly framed as a proof-of-concept investigation, not a test of clinical efficacy. Its goal was to establish biological plausibility before committing to larger, longer, and more expensive trials. Prior work in Alzheimer's mouse models had shown that D+Q reduces senescent cell burden in the brain and improves cognitive markers, making human translation a logical next step.
Because the trial is completed but results have not been published in a peer-reviewed journal accessible for this summary, the specific CSF drug concentrations and any preliminary biomarker findings remain unavailable here. If confirmed, CNS penetration would open the door to efficacy trials examining whether senolytic therapy can slow or halt AD progression — a fundamentally different mechanism from existing amyloid-targeting therapies.
The trial underscores a broader shift in Alzheimer's research toward targeting the aging biology underlying neurodegeneration, not just its downstream protein accumulations. This senomorphic and senolytic approach may ultimately complement, rather than replace, existing treatment strategies.
Key Findings
- Trial tested whether the senolytic drug pair dasatinib + quercetin penetrates the brain via CSF measurement in early AD patients.
- Study is completed (Phase 1/2), representing the first human CNS pharmacokinetic test of D+Q in Alzheimer's disease.
- Prior mouse model data showed D+Q reduces brain senescent cell burden and improves AD-related biomarkers.
- CNS penetration confirmation would be a prerequisite for larger efficacy trials in Alzheimer's patients.
- Approach targets cellular senescence as a driver of neurodegeneration — distinct from amyloid or tau-focused therapies.
Methodology
This was a Phase 1/2 proof-of-concept pilot study enrolling older adults with early Alzheimer's disease. The primary outcome was pharmacokinetic: detection of dasatinib and quercetin in cerebrospinal fluid collected from participants after drug administration. The trial was sponsored by UT Health San Antonio and is now completed.
Study Limitations
This summary is based on the abstract and trial registry entry only — full results and outcome data have not been reviewed. The study is a small pilot not powered to detect clinical efficacy. No peer-reviewed publication of results was available at time of summary.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.